Very low birth weight (VLBW) neonates are at high risk of glycemic disorders. Neonates requiring intensive care have impaired glucose control and a wide fluctuation in blood glucose levels. Their developing brain is likely to be more susceptible to these metabolic insults. Hypoglycemia is associated with poor neurodevelopmental outcome [
1‐
3] and hyperglycemia is correlated with increased mortality and morbidity in preterm infants [
4]. Plasma glucose level detection represents the gold standard to diagnose these metabolic disorders, however, this method produces only punctual values and does not allow a real-time (RT) monitoring of glycaemia and its trends. This could explain the great deal of controversy over the values of normoglycemia in neonatal population and the paucity of proper diagnoses [
5,
6]. Specifically, there is no consensus on the definition of “significant hypoglycemia” (blood glucose values requiring a medical treatment), and on the threshold of glucose concentration and the time needed to cause neurological damage [
7,
8]. Continuous glucose monitoring (CGM) can be used to investigate glucose homeostasis during the neonatal period and some studies showed its use is safe and reliable [
8‐
10]. Moreover, it is demonstrated that CGM can detect a significantly higher number of hypo/hyperglycemia episodes as compared to intermittent blood glucose measurement. A better management of glucose administration [
11] can be obtained with a RT visualization of glycemic values in the new generation CGM system (CGMS) [
12‐
14]. Recently, however, some authors expressed concerns about using CGM in the clinical setting [
15]. In fact, they showed that the calibration methods of new generations CGM sensors are designed for higher glucose concentrations of children and adults, and not for neonates. Therefore, the routine usage of a CGMS with its specific sensor, could be proposed only after validation studies conducted in a neonatological setting. This study was conducted using RT Medtronic’s CGMS, a system previously tested by our research group in a population of neonates at risk of dysglycemia with a median gestational age (GA) of 32 weeks. Not many dysglicemic episodes were detected, but the CGMS demonstrated reliable in the normoglycemic range [
12]. Only VLBW neonates fed by parenteral nutrition were included in this study, with the aim of testing the reliability of the Medtronic’s CGMS in this specific new setting. Babies had a lower mean gestational age and birth weight than in the previous study, and both hyper- and hypoglycemic episodes were detected during the study period. We also aimed at describing the distribution of glycemic values in the studied population. Such data is currently lacking in the scientific literature [
16] for VLBW infant requiring parenteral nutrition, but it could be very useful to allow a proper modulation of the glucose infusion, thus preventing dysglycemic episodes, to reduce and optimize the need of insulin therapy, and hopefully to lead to the definition of a new protocol for a strict glycemic control in randomized controlled trials.